• Record full-year revenue of A$29.2 million for FY25, up 23% on prior year
• Glaucoma segment achieved positive EBITDA in H2 FY25
• Group targeting breakeven EBITDA in H1 FY26 and continuing cashflow improvement

Nova Eye Medical Limited (ASX: EYE), a medical technology company focused on advanced ophthalmic treatment technologies and devices, has reported a record sales performance for the 2025 financial year. Total group revenue for FY25 reached A$29.2 million (US$18.8 million), marking a 23% increase on the prior year. Second-half sales of A$16.2 million (US$10.4 million) were up 51% on the prior corresponding period and in line with guidance. The glaucoma segment achieved an EBITDA of US$65,000 (unaudited) in H2 FY25, a substantial improvement on H1. At a group level, the second-half EBITDA loss was US$2.1 million lower than H1 FY25, driven by sales growth and gross margin improvement. The company's quarterly group cash outflow from operations was A$847,000, representing a continuation of the downward trend. Cash on hand as of 30 June 2025 was A$5.1 million. For FY26, Nova Eye Medical expects sales revenue (excluding China) to range between US$21 million and US$24 million (A$32 million to A$37 million) and the group is currently expected to achieve breakeven EBITDA in H1 FY26.

FY26 sales revenue (excluding China) expected to range between US$21 million and US$24 million (A$32 million to A$37 million). The group is currently expected to achieve breakeven EBITDA in H1 FY26.

The company is targeting breakeven EBITDA in H1 FY26 and continuing cashflow from operations improvement. It is also progressing approval by the regulatory authority in China of its iTrack™ Advance product and assessing opportunities for its iTrack™ technology in targeted drug delivery.